Search Results - Gengwei Huo

Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis by Gengwei Huo, Gengwei Huo, Wenjie Liu, Shuo Kang, Peng Chen

Connect to this object online.

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer by Wenjie Liu, Wenjie Liu, Wenjie Liu, Wenjie Liu, Gengwei Huo, Gengwei Huo, Gengwei Huo, Gengwei Huo, Peng Chen, Peng Chen, Peng Chen, Peng Chen

Connect to this object online.

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer by Gengwei Huo, Gengwei Huo, Gengwei Huo, Gengwei Huo, Ying Song, Wei Liu, Wei Liu, Wei Liu, Wei Liu, Hua Guo, Hua Guo, Hua Guo, Hua Guo, Peng Chen, Peng Chen, Peng Chen, Peng Chen

Connect to this object online.

First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States by Wenjie Liu, Gengwei Huo, Peng Chen

Connect to this object online.

Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States by Gengwei Huo, Ying Song, Wenjie Liu, Xuchen Cao, Peng Chen

Connect to this object online.